GlassScriptPhysician profile
Vijay Patel
NPI 1124136676
$7,027.23
in general payments reported to CMS, 2019-2025
24 companies · $83.57 in 2025
The $83.57 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $1,004 · 2021: $4,387 · 2022: $287 · 2023: $641 · 2024: $102 · 2025: $83.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479 · Travel and Lodging: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.62 |
| Travel and Lodging | $348.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,402.91 | 2019-2023 | Farxiga |
| Abbott Laboratories | $348.16 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Otsuka America Pharmaceutical, INC. | $300.69 | 2019-2023 | Jynarque |
| Genentech USA, INC. | $118.14 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.69 | 2022-2023 | |
| Intuity Medical INC | $102.64 | 2022 | |
| Csl Behring | $101.75 | 2024 | Hizentra |
| Dendreon Pharmaceuticals LLC | $83.57 | 2025 | Provenge |
| Fresenius USA Marketing, INC. | $78.80 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $50.61 | 2019-2023 | Rayaldee |
| Aurinia Pharma U.S., INC. | $50.15 | 2023 | Lupkynis |
| Baxter Healthcare | $44.43 | 2020-2021 | |
| Biomerieux INC | $39.46 | 2019-2021 | |
| Amgen INC. | $27.76 | 2019 | |
| Travere Therapeutics, INC. | $26.98 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $25.14 | 2023 | Acthar |
| Novo Nordisk INC | $23.70 | 2023 | Ozempic, Rybelsus |
| Genzyme Corporation | $23.21 | 2023 | |
| Vifor Pharma, INC. | $17.15 | 2019 | |
| Horizon Therapeutics Plc | $16.97 | 2020 | |
| Alexion Pharmaceuticals, INC. | $16.37 | 2019 | |
| Karyopharm Therapeutics INC. | $13.95 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.